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Abstract
Objective: To analyze whether for an equal health problem
there are gender differences in the drugs used in an adult po-
pulation attended in the Health Care Centers of the Valencian
Community (Spain).
Methods: A cross-sectional analytical study was carried out
between February-August 1997. The independent variables
were: socio-economic parameters, frequency of visits, and self-
perceived or diagnosed health problems, and the dependent
one the number of drugs consumed.
Results: Of the 812 patients considered, 801 consumed me-
dication. Eighty percent of the health problems for which drugs
were used involved 5 apparatuses and systems (mean: 3.3
health problems/patient). The 5 most consumed therapeutic
groups accounted for 81% of the total (mean: 4.5 drugs/pa-
tient). Significant differences were recorded, with greater fe-
male consumption in the central nervous system and geni-
tourinary tract therapeutic groups, and with greater male
consumption in relation to the respiratory system and syste-
mic anti-infectious therapy. Drug use increased with age, lo-
west educational level, lowest professional categories, and with
the highest frequency of visits to the physician. Significant dif-
ferences were also recorded in drug use by occupational sta-
tus, marital status and family structure. The multivariate analy-
sis showed the number of health problems and the frequency
of visits accounted for 82.2% of the variability of the variable
«number of drugs consumed». The variability accounted for
by gender was explained by the variable health problems, the
main factor underlying drug consumption among women and
men.
Conclusion: The main finding is probably that women do not
use larger numbers of drugs than men if health problems and
frequency of visits are controlled.
Key words: Gender differences. Drugs. Health problems.
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Resumen
Objetivo: Analizar si para el mismo problema de salud hay
diferencias de género en los medicamentos utilizados en una
población adulta atendida en centros de salud de la Comu-
nidad Valenciana.
Métodos: Estudio observacional transversal analítico realizado
entre febrero y agosto de 1997. Variables independientes: pa-
rámetros socioeconómicos, frecuentación de los servicios de
salud y problemas de salud autopercibidos o diagnosticados.
Variable independiente: número de medicamentos consumidos. 
Resultados: De los 812 pacientes, 801 tomaban medicamen-
tos. El 80% de los problemas de salud por los que se medica-
ban pertenece a 5 aparatos y sistemas (media: 3,3 problemas
de salud por paciente). Los 5 grupos terapéuticos más consumidos
suponen el 81% del total (media: 4,5 medicamentos por pacien-
te). Se evidenció un mayor consumo significativo por la mujer de
medicamentos de los grupos terapéuticos del sistema nervioso
central e infecciones genitourinarias, y mayor consumo por los va-
rones de medicamentos de los grupos terapéuticos del sistema
respiratorio y terapia antiinfecciosa sistémica. El uso de los me-
dicamentos incrementó con la edad, el menor nivel educativo, menor
categoría profesional y con la mayor frecuencia de visitas. Tam-
bién se encontraron diferencias significativas en el uso de medi-
camentos según la situación laboral, estado marital y la estruc-
tura familiar. El análisis multivariante mostró que el número de
problemas de salud y la frecuencia de visitas explicaban el 82,2%
de la variabilidad de la variable «número de medicamentos con-
sumidos». La variabilidad representada por el género se explicó
por la variable de problemas de salud, el principal factor subya-
cente del consumo de medicamentos entre mujeres y hombres.
Conclusiones: El hallazgo principal es, probablemente, que
las mujeres no utilizan mayor número de medicamentos que
los hombres al ajustar por problemas de salud y la frecuen-
cia de las visitas.
Palabras clave: Diferencias de género. Medicamentos. Pro-
blemas de salud. Estudio transversal. Atención primaria. 
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Introduction
S
everal studies have associated the female gen-
der with increased drug consumption. Poorer self-
perceived health, self-medication practices and
a greater use of the available health services on
the part of women have been some of the causes sug-
gested to explain the differences found. The increased
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consumption of medication has also been related to edu-
cational level, occupational and marital status, and he-
alth problems1-10.
One of the foremost aims of the World Health Or-
ganization (WHO) has been to reduce health inequali-
ties among different social groups 25% by the year 2000.
In this context, the WHO considers health care itself,
among other causes, as one of the factors favoring ine-
qualities in terms of health11,12. Under conditions of equal
patient demands or complaints, such inequalities can
manifest as differences in access to health care, variable
diagnostic and/or treatment efforts or access to the be-
nefits afforded by technological advances, which are fun-
damentally concentrated in hospitals13-15. Such diffe-
rences in relation to patient gender would be the
consequence of what Dreachslin16 has termed «patient
gender bias», and Healy17 described as the «Yentl syn-
drome», in reference to the presumed need for women
to disguise themselves as males to secure the same
quality access to health care as males.
The increased accessibility, the high frequency of con-
sultations for banal problems, and other characteristics
typical of the primary care setting could lead to incre-
ased utilization of the first level of health care by women,
and to an increased tendency towards symptomatic phar-
macological treatment. It has also been suggested that
professionals may be more prone to prescribe medica-
tion to women than to men for the same health pro-
blems14,18.
In a previous paper, we suggested the influence of
gender upon the quality of medicine, by pointing to the
greater likelihood for women between 45 and 64 years
of age to take lower quality medication. In addition, it
showed the effect of where the prescription was issued
and of health problems in explaining this difference in
consumption19.
The aim of the present study is to analyze whether
for an equal health problem there are gender differen-
ces in the profile of drugs used in an adult population
attended in a primary care setting.
Methods
A cross-sectional analytical study was made invol-
ving patients selected for an evaluation of the quality
of drug use, taking into consideration the percentage
distribution of the population in the three provinces that
conform the Valencian Community (Spain) (total popu-
lation: approximately four million), between February and
August 1997.
The selection of Health Care Centers was made ta-
king into account their accessibility, feasibility and ge-
ographical distribution. Thirteen primary care centers
were included, pertaining to 11 health areas, with an
approximate population of 274,000 inhabitants; of
these, 98.5% belonged to urban nuclei. The patients
were recruited by consecutive sampling of both sexes
equally when visiting the Health Care Center. A total of
431 individuals of each sex was calculated for the com-
parison of proportions to detect a difference of  10%
( = 0.05,  = 0.20 in bilateral contrasting, estimating
a loss rate of 10%). This size suffices to detect a diffe-
rence in the number of drugs between sexes of 0.65 or
higher, assuming a standard deviation (SD) of 3, a risk
 = 0.05,  = 0.20, and a loss rate of 10%.
The inclusion criteria were patient age over 14 years
and the obtainment of informed consent. The exclusion
criterion was the presence of cognitive impairment not
allowing a normal patient interview.
The following data sources were used: a structu-
red questionnaire in which the items explored socio-
economic aspects, the frequency of health care visits
(measured in terms of the time elapsed since the last
visit to the family physician: never before; more than 
12 months before; between 2 and 12 months before; in the 
last 2 months), information on drugs used at the time
of the visit (both prescribed medication and self-medi-
cation), linked to the indication for which the drugs were
used. For this latter purpose data were collected on the
use of drugs for health related problems at the time of
the visit (structured according to the common disorders
self-perceived by the population, and according to phar-
maceutical forms)20. The drugs recorded (including pres-
cribed medication and self-medication) were grouped
according to the International Anatomical Classification
of the Pharmaceutical Specialities Catalogue21, consi-
dering any pharmaceutical specialities not contempla-
ted in the catalogue as representing non-catalogued me-
dication. Data collection was carried out by three
interviewers. Patients were aware that this questionnaire
formed part of research work, but as a study on the use
of medication and traffic accidents.
Data were completed and confirmed using medical
records and the long-term treatment card, this being a
document widely used in Spanish primary care, reflecting
the medication authorized for prolonged treatment
(i.e., with a duration of more than one month) in patients
with chronic illnesses. In order to assess the reliability
of the questionnaire, an analysis was made of 30 sur-
veys involving the same users with a separating inter-
val of two weeks; the general concordance index (po)
was 96.7%.
The descriptive analysis was based on the chi-squa-
re test for the comparison of proportions, while the Stu-
dent t-test and analysis of variance (ANOVA) were used
for the comparison of means. The main results are spe-
cified with the corresponding 95% confidence intervals
(95%CI). A multivariate analysis involving multiple linear
regression was made to investigate the effect of gen-
der upon the number of drugs, and to control for the be-
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havior of the rest of variables as confounding factors;
the variables included were grouped in accordance to
the results of the stratified analysis. The interaction term
«number of health problems * gender» was controlled
for. An analysis was made of the application postula-
tes of the multiple linear regression model, i.e., good-
ness of fit and the presence of outliers. Emphasis of choi-
ce was placed on the model that yielded the most precise
estimation of the association – stressing validness over
precision. Two models were generated: Model 1 com-
prising all the predictive variables and the interaction term
«number of health problems * gender», the latter term
being excluded from the model due to a lack of signi-
ficance in the chunk test. In turn, Model 2 comprised
the significant predictive variables number of health pro-
blems and frequency of visits.
Results
Of the 862 questionnaires, 50 (5.8%) were excluded
on the grounds that they were illegible and/or incom-
plete. The loss rate was therefore lower than expected
(10%). Nobody refused to participate in the study. A total
of 812 patients were finally included in the study; of these,
801 (98.6%) were taking medication. Table 1 shows the
age and gender characteristics of these patients.
Health problems and drug use by therapeutic groups by gender
The 801 patients referred a total of 2.622 health pro-
blems, with an average of 3.27 (SD 2.22) problems per
patient. Females reported 1447 (55.2%) health problems,
versus 1.175 among the men. The analysis revealed sig-
nificant differences in terms of gender (p < 0.001), with
a female predominance in pathology of the nervous sys-
tem and genitourinary tract. A non-significant male pre-
dominance in respiratory, skin and sensory organ di-
seases was observed (table 1).
The 3.634 different drugs consumed by the 801 users
were distributed into 12 therapeutic groups. The 5 most
consumed groups accounted for 81% of the total, and
comprised the digestive apparatus and metabolism, ner-
vous system, cardiovascular system, locomotor appa-
ratus and respiratory system. A total of 54.8% of the
drugs were consumed by the 410 females in the sam-
ple. Significant differences (p < 0.001) were observed
in drug consumption by therapeutic groups and patient
gender. These differences were recorded in the thera-
peutic groups central nervous system and genitourinary
tract – with greater female consumption (percentage dif-
ference 4.5; 95%CI, 1.8-7.2 and 1.9; 95%CI, 0.9-2.9,
respectively), and in respiratory system and systemic
anti-infectious therapy, with greater male consumption
(percentage difference 5.2; 95%CI 3.3-7.1 and 1.7; 
95% CI 0.7-2.8, respectively) (table 2).
By therapeutic subgroups, women showed a grea-
ter use of mineral supplements (excluding iron), antia-
nemic agents, antihemorrhoidal and antivaricose drugs,
psycholeptics and psychoanaleptics. In comparison, men
showed a greater consumption of antacids, antiflatulence
and antiulcer drugs, antidiabetic, antigout, and anti-
parkinson drugs, as well as antiasthmatic, anti-influen-
za and antitussive medication (table 2).
Variables associated to drug use by gender
The mean number of drugs consumed per person
was 4.5 (SD 3.2); 54.6% (95%CI, 51.1-58.8) of the pa-
tients consumed more than 3 drugs. Drug use increa-
sed with age and the female sex (p < 0.001). The re-
lationship was significantly higher in women aged 45-64
years (fig. 1). Significant differences (p < 0.001) were
also seen in drug use by educational level, and pro-
fessional, occupational and marital status. Table 3 shows
the mean drug consumptions distributed by predictive
variables and gender groups. The number of drugs used
was found to decrease with increasing educational level
Table 1. Patient distribution by age health and gender
Gender
n (%) Women Men
n (%) n (%)
Age (years)a
14-29 124 (15.5%) 58 (46.8%) 66 (53.2%)
30-44 146 (18.2%) 76 (54.3%) 70 (45.7%)
45-64 263 (32.8%) 146 (55.5%) 117 (44.5%)
Over 64 268 (33.5%) 130 (48.5%) 138 (51.5%)
Total 801 (100.0%) 410 (51.2%) 391 (48.8%)
Health problems by apparatus 
and systemsb
Cardiovascular 482 (18.4) 273 (18.9) 209 (17.8)
Locomotor 470 (17.9) 253 (17.5) 217 (18.5)
Endocrine and metabolism 169 (6.4) 86 (5.9) 83 (7.1)
Respiratoryc 198 (7.6) 91 (6.3) 107 (9.1)
Nervousc 370 (14.1) 235 (16.2) 135 (11.5)
Genitourinary 124 (4.7) 86 (5.9) 38 (3.2)
Digestive 498 (19.0) 257 (17.8) 241 (20.5)
Skin and sensory organs 269 (10.3) 132 (9.1) 137 (11.7)
Other 42 (1.6) 34 (2.3) 8 (0.7)
Total 2,622 (100) 1,447 (55.2) 1,175 (44.8)
aPercentage vs. total age group.
bPercentage of total by health problems and gender. Mean of 3.53 (standard de-
viation [SD] = 2.35; 95%CI, 3.30-3.76) health problems for women; mean of 3.01
(SD = 2.04; 95%CI, 2.80-3.21) health problems for men.
cSignificant differences between sexes (p < 0.05).
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and professional categories. The analysis of differen-
ces by gender showed that –with the exception of the
illiterate subjects– women consumed more drugs.
These differences was statistically significant at the com-
plete primary education level (difference of the means
1.0; 95%CI, 0.2-1.8) and in the lowest professional ca-
tegory, where 76% were involved in domestic activities
(difference of the means 2.0; 95%CI, 1.1-2.8). Hou-
sewives and inactive subjects were those who consu-
med most medication. Moreover, widowers were found
to consume most drugs, and either married or divor-
ced individuals used more drugs than single subjects
(difference of the means 2.0; 95%CI, 0.8-3.2). Married
women or widows consumed more drugs than men (dif-
ference of the means 0.7; 95%CI, 0.1-1.2). Grouping
of the family structure into 2 categories showed signi-
ficant differences (p < 0.01) in the sense of increased
drug use in nucleated families (difference of the means
1.0; 95% CI, 0.5-1.7), and also an increased use of me-
dication among women belonging to a nucleated family
(difference of the means 0.7; 95%CI, 0.2-1.2). In turn,
significant differences were recorded in drug con-
sumption according to the time elapsed since the last
visit to the primary care center (p < 0.001). In effect,
drug use was found to increase with the frequency of
visits. The analysis of the 4 visiting frequency levels and
their distribution by gender revealed increased drug con-
sumption among women, with significant differences in
the highest frequency (fig. 2).
Results of the multivariate analysis: linear regression
Table 4 shows the results of the application of the
two models described under Methods’ section, where
the value of the F-test was found to be significant in both.
As a result, the variability accounted for by the equa-
tions was significant in the two models. Analysis of Model
1 showed the variability accounted for by the model to
be 0.8, and the regression coefficients of the variables
Table 2. Patient distribution by therapeutic groups subgroups and gender
Gender
Women Men
n (%) n (%) n (%)
Therapeutic groups and subgroupsa
A. Gastrointestinal tract and metabolism 793 (21.7) 433 (21.7) 360 (21.9)
Antidiabetic medication 33 (1.7) 51 (3.1)
Antiacids, antiflatulence and antiulcer drugs 155 (7.8) 166 (10.1)
Mineral supplements excluding iron 45 (2.3) 8 (0.5)
B. Blood and blood forming organs 110 (3.03) 66 (3.31) 44 (2.68)
Antianemic drugs 22 (1.1) 3 (0.2)
C. Cardiovascular system 629 (17.3) 366 (18.4) 263 (16.0)
Antihemorrhoidal and antivaricose agents 151 (7.6) 61 (3.7)
D. Dermatologicals 158 (4.4) 76 (3.8) 82 (5.0)
G. Genitourinary system and sex hormonesb 96 (2.6) 70 (3.5) 26 (1.6)
J. Anti-infectives for systemic useb 92 (2.5) 35 (1.8) 57 (3.5)
M. Musculoskeletal system 389 (10.7) 201 (10.1) 188 (11.5)
Antigout agents 3 (0.2) 23 (1.4)
N. Nervous systemb 787 (21.7) 472 (23.7) 315 (19.2)
Psycholeptics 126 (6.3) 69 (4.2)
Psychoanaleptics 39 (2.0) 18 (1.1)
Antiparkinson drugs 1 (0.1) 7 (0.5)
R. Respiratory systemb 322 (8.9) 130 (6.2) 192 (11.7)
Antiasthmatics 50 (2.5) 90 (5.5)
Anti-influenza and antitussive drugs 39 (2.0) 56 (3.4)
S. Sensory organs 114 (3.1) 61 (3.1) 53 (3.2)
Other 67 (1.8) 45 (2.3) 22 (1.3)
Not catalogued 77 (2.1) 38 (1.9) 39 (2.4)
Total 3,634 (10.0) 1,993 (54.8) 1,641 (45.2)
aPercentage of total drugs by gender. Mean of 4.86 (standard deviation [SD] = 3.30; 95%CI, 4.54-5.18) drugs for women; mean of 4.20 (SD = 2.95; 95%CI, 3.90-4.49)
drugs for men.
bSignificant differences between sexes (p < 0.05). Table only includes the subgroups statistically different between sexes.
«health problems» and «frequency of visits» were sig-
nificant. In Model 2, the value of the residuals, that of
the fitted determination coefficient and the regression
coefficients of the variables «health problems» and «fre-
quency of visits» were similar to those of Model 1 (non-
confounding with the rest of variables). The optimum
model for explaining the value of gender was Model 1,
since it takes into account all the predictive variables
studied, without losing valuable accuracy. These data
show that: a) the number of health problems and the
frequency of visits explain 82.2% of the variability of the
variable «number of drugs consumed», and b) for each
health problem 1.3 drugs are consumed, fitted for all the
predictive variables studied.
Discussion
The main finding of this study is probably that women
do not use larger numbers of drugs than men if health
problems and frequency of visits are controlled in the
multivariate analysis. Although many studies have in-
vestigated the use of drugs and the role of different va-
riables as predictors of drug consumption, it is not easy
to establish comparisons among studies, since different
populations, information sources and methods are in-
volved1,2,6-10,20,22,23.
This work has the usual limitations of a cross-sec-
tional survey. The aim of the study was to compare the
use of drugs by patient gender, and in this sense there
are no reasons to believe that the selection of patients,
centers and seasonal pathology may have influenced
comparison of the groups. The behavior of some of the
predictive variables as confounding factors was controlled
in the analytical stage by means of multivariate analy-
sis and through stratification in the bivariate analysis.
The strategies used for the collection of data based on
prescription and self-medication data related to the he-
alth problems leading to consumption allowed us to con-
trol information bias and secure improved quality infor-
mation.
Drug use by therapeutic groups
Our results show 80% of the medication consumed
to correspond to five therapeutic groups. Although the
order may vary, the most frequently consumed thera-
peutic groups reported in the literature essentially
coincide with our own findings1,10,20,22-25. By therapeutic
subgroups, our observation that women consume more
psycholeptics and psychoanaleptics coincides with the
published reports1,6,18,20,23-25. Our results agree with those
reporting female consumption to be greater in relation
to psychotherapeutic agents, with no gender differen-
ces in relation to cardiovascular drugs and diuretics1,24.
However, other studies have reported differences in re-
lation to these last therapeutics groups, central nervous
system, nutritional or hematological medication23,25.
In the descriptive analysis, the present results show
that women in global terms consume more medication
than men, and that drug use increases with age. These
findings coincide with the literature, though in our case
significant differences by gender were only observed for
the 45-64 years age group2-4,6,8,10,16,20,26,27. In contrast, Kot-
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Figure 1. Mean drug consumption, distribution by age and gender.
zan et al2, in a study of the Medicaid population, found
no gender differences in the number of drugs prescri-
bed per patient. These authors explain this result in terms
of a poor health status among the males of the study
population involved. Our results coincide in reflecting in-
creased drug use at the lower educational and social
levels6,8,22,26,27, and are consistent with those of Payne
et al10, who found education to be a predictor of medi-
cation use. Moreover, women were seen to consume
more drugs at all social levels, though the differences
only reached statistical significance in the category fun-
damentally comprising housewives. The higher drug use
observed among inactive individuals and housewives
was probably related to patient age, since 91% of the
housewives were over age 45, and 76% of the inacti-
ve individuals were over 65 years old. However, hou-
sewives consumed more drugs than the inactive users
despite being younger – an observation that could be
related to gender (99% of the users engaged in domestic
activities corresponding to women, while 74% of the inac-
tive subjects were males), the social role of women in-
volved in domestic activities, and to morbidity. These con-
siderations would be in line with the results of Rohlfs
et al28, indicating that both young and mature house-
wives consume more medication than women who are
either actively employed or unemployed. In agreement
with other studies6,22, widows and widowers consume
most drugs, though we believe this could be linked to
both patient age (80% over age 65) and morbidity (more
health problems than in the average population).
The frequency of visits to primary care centers has
been associated to increased drug use both in our study
16
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Table 3. Number of patients and mean drug consumption. Distribution by predictive variables and gender
Socioeconomic variables Total n; mean (SD) Women n; mean (SD) Men n; mean (SD)
Educational status
Cannot read or write 41; 5.4 (2.5) 33; 5.2 (2.4) 8; 6.1 (3.0)
Can read and/or write 152; 5.8 (3.4) 84; 6.0 (3.7) 68; 5.4 (3.2)
Incomplete primary 131; 4.6 (3.2) 65; 4.9 (3.3) 66; 4.4 (3.2)
Complete primarya 232; 5.1 (3.2) 114; 5.6 (3.3) 118; 4.6 (2.9)
Higher but non-university 158; 3.3 (2.6) 67; 3.5 (2.8) 91; 3.2 (2.4)
University 84; 2.6 (1.8) 44; 2.7 (2.1) 40; 2.4 (1.4)
Not indicated 3; 2.7 (2.1) 3; 2.7 (2.1) –
Occupational status
Activea 278; 3.3 (2.5) 117; 3.7 (2.9) 161; 3 (2.3)
Seeking first employment 15; 2.5 (1.8) 8; 2.1 (1.6) 7; 3.0 (1.9)
Unemployed (has worked) 61; 4.1 (2.8) 31; 4.6 (2.7) 30; 3.6 (2.9)
Inactive (retired, transient incapacitation) 236; 5.4 (3.2) 61; 4.9 (3.2) 175; 5.5 (3.2)
Studenta 34; 3.1 (2.1) 17; 2.2 (1.5) 17; 3.9 (2.3)
Domestic activities 173; 6.0 (3.4) 172; 6.0 (3.4) 1; 1.0
Not indicated 4; 6.3 (6.7) 4; 6.3 (6.7) –
Professional category
Directors and higher technicians 24; 2.7 (1.5) 10; 2.7 (1.3) 14; 2.6 (1.6)
Middle technicians 64; 3.1 (2.4) 28; 3.5 (2.7) 36; 2.8 (2.2)
Specialized non-manual workers 91; 4.7 (2.8) 40; 4.9 (2.8) 51; 4.5 (2.7)
Specialized manual workers 237; 4.9 (3.0) 51; 5.5 (3.2) 186; 4.8 (3.0)
Non-specialized workers 157; 4.5 (3.3) 81; 5.0 (3.3) 76; 4.0 (3.4)
Not classifiablea 228; 4.7 (3.4) 200; 4.9 (3.5) 28; 3.0 (1.8)
Marital status
Single 167; 3.2 (2.4) 73; 3.4 (2.7) 94; 3.1 (2.1)
Married/couplea 508; 4.9 (3.3) 253; 5.2 (3.5) 255; 4.5 (3.1)
Widow/widower 92; 5.2 (3.0) 62; 5.3 (2.8) 30; 5.1 (3.5)
Divorced/separated 32; 4.3 (3.2) 20; 4.9 (3.6) 12; 3.5 (2.4)
Not indicated 2; 1.5 (0.7) 2; 1.5 (0.7) –
Family structure
No nucleus 129; 3.7 (2.8) 72; 4.0 (2.8) 57; 3.3 (2.8)
One or more nucleia 660; 4.7 (3.2) 333; 5.1 (3.4) 327; 4.4 (3.0)
Not indicated 12; 2.3 (1.7) 5; 2.4 (2.1) 7; 2.1 (1.5)
n: number of patients; mean: mean of drugs consumed by patient; SD: standard deviation. 
aSignificant differences between sexes (p < 0.05). Not classifiable includes person seeking first employment, person not declaring any occupation, domestic activities and
students.
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p < 0.05
Figure 2. Mean drug consumption, distributed by frequency of visits (measured as time elapsed since last visit) and gender. 
Table 4. Model summaries explaining the number of drugs consumed
Analysis of variance
Multiple R Adjusted R square Sum of squares (DF) F p
Regression Residual
Model 1 0.91 0.83 6,331.19 (9) 1,326.54 (769) 407.80 < 0.001
Model 2 0.91 0.82 6,494.51 (2) 1,401.57 (790) 1,830.33 < 0.001
Variables  (standard error) Confidence interval Beta T p
Model 1 Constant 0.03 (0.215) –0.391-0.451 0.139 0.890
Gender –0.043 (0.097) –0.233-0.147 –0.007 –0.441 0.659
Age 0.002 (0.004) –0.005-0.009 0.013 0.595 0.552
Family structure 0.04 (0.143) –0.243-0.318 0.004 0.264 0.792
Occupational status 0.151 (0.118) –0.079-0.382 0.023 1.29 0.198
Frequency of visits 0.252 (0.113) 0.031-0.473 0.035 2.24 0.026
Marital status 0.007 (0.152) –0.291-0.305 0.001 0.046 0.963
Educational status –0.023 (0.118) –0.254-0.208 –0.004 –0.194 0.846
Professional category –0.058 (0.124) –0.302-0.186 –0.008 –0.467 0.641
Health problems 1.261 (0.023) 1.216-1.306 0.894 54.5 0.000
Model 2 Constant 0.137 (0.110) –0.079-0.352 1.247 0.213
Health problems 1.277 (0.022) 1.235-1.320 0.899 59.1 0.000
Frequency of visits 0.286 (0.110) 0.070-0.502 0.039 2.597 0.010
Model 1: includes all the predictive variables; Model 2: includes the variables n.o of health problems and frequency of visits; dependent variable: n.o of drugs consumed;
R: correlation coefficient; DF: degrees of freedom; F: F test for comparison of variances; T: statistic; CI: 95% confidence interval for B; recoding multivariate analysis: gen-
der: 0. male, 1. female; age: years; family structure: 0. no nucleus, 1. one or more nuclei; occupational status: 0. active, 1. seeking first employment, unemployed, inacti-
ve, student or domestic activities; frequency of visits: 0.> 2 months 1.< 2 months; marital status: 0. single 1. married/couple, widow/widower or divorced/separated; edu-
cational status: 0. high educational level (complete primary, higher but non-university and university studies), 1. low educational level (cannot read or write, can read
and/or write and incomplete primary); professional category: 0. high professional category (directors and higher technicians, middle technicians, specialized non-manual
workers), 1. low professional category (specialized manual workers, non-specialized workers, not classifiable); health problems: number.
DF: degrees of freedom.
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and elsewhere in the literature6,7,10,22,26. The fact that
women make use of health services more often than
men has already been documented6,10,20,26,28. However,
in coincidence with the description of Payne et al10 re-
garding the proportion of Canadian women reporting me-
dication use increments with the number of physician
visits, on analyzing consumption in our series by fitting
to the frequency of visits, we found that women conti-
nue to use more drugs than males in all frequency ca-
tegories. Drug consumption is obviously related to the
existence of health problems. The mean number of pro-
blems for which our patients consumed drugs was again
greater among women than in men – in agreement with
other authors6,10,20,22. In our case, the number of health
problems recorded was higher than in the study by
López-Torres et al22, who only considered chronic he-
alth problems in elderly patients, and not perceived mor-
bidity as in both our case and in the Health Survey of
the Valencian Community20.
Results of the multivariate analysis
In the study by Roe et al23 using a database with phar-
macy claim and eligibility information, gender differen-
ces in medication are reported in several classes of me-
dications, including antidepressants and antianxiety and
pain medication. However, the authors did not investi-
gate the possible causes of such differences, and mo-
reover claimed that future research should be conduc-
ted to afford better understanding of the role of
socioeconomic status, ethnicity, and geographic region.
In this sense, the increased drug consumption associated
with the female gender, advanced age, a low educational
level, lower professional categories or housewife sta-
tus, and inactivity or unemployment –documented both
in our study and elsewhere in the literature– fails to sus-
tain statistical significance when taking into account the
number of health problems and the frequency of visits
in the multivariate analysis. In this way, the Women’s
Health Surveillance Report from the Canadian Institu-
te for Health Information reported that medication use
increases with a greater number of chronic diseases,
physician visits, and age10. In contrast, Van der Waals
et al29 concluded that the gender difference among ben-
zodiazepine users seems to be due to general practi-
tioners being less stringent when prescribing these drugs
for women. We agree with Eggen6, who considered that
health problems (in terms of number) are the best pre-
dictor of drug use. Only the more frequent utilization of
health services, controlling for the rest of variables (in-
cluding the number of health problems), conditions in-
creased drug consumption. If, as suggested by our re-
sults and those of Payne et al10, health problems are
effectively the main factor underlying increased drug con-
sumption among women, then historical factors (e.g.,
social discrimination) could cause women to become
ill more often or feel more ill – thus leading to increa-
sed drug consumption28. If this were not the case, then
patient gender bias could manifest through the tendency
of physicians to overdiagnose women and/or under-
diagnose males –thereby prescribing more drugs
among the former– but not through a greater or lesser
accessibility to medication on the part of women29. The
gender of patients and/or doctors may condition the diag-
nosis of illness, though once the patients are diagno-
sed, health problems are the main factor underlying drug
consumption among both women and men.
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Comment. Drug utilization studies. The need to
know the indication
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This study deals with the analysis of the factors as-
sociated with drug utilization and is therefore a phar-
macoepidemiology study and, specifically, a drug utili-
zation study (DUS)1.
Although abundant literature on the subject has been
published, each new study in this field contributes com-
plementary information, specific to the population stu-
died, since a large proportion of the factors determining
drug utilization are sociodemographic; consequently,
these studies generally have little external validity.
In the present study, the patients were recruited from
health centers and their characteristics, as well as data
on drug utilization, were gathered through a question-
naire. Although constructing a primary database can con-
fer researchers with greater freedom and allow the va-
riables gathered specifically for the study to be studied,
the potential of secondary sources such as the Natio-
nal Health Survey or the Pharmaceutical Billing Data-
base2, the latter in combination with the Health Identi-
fication Card, should not be underestimated. In addition
to efficiency, both databases are representative of the
population in a way that is difficult to achieve in data-
bases generated specifically for a particular study.
However, secondary databases also present major
limitations. Pharmaceutical Billing Databases, for exam-
ple, do not contain information on the indication moti-
vating the drug prescription, making studies of indica-
tion-prescription and prescription-indication impossible2.
And these are, in our opinion, precisely the designs cu-
rrently required in DUS in Spain.
The Database for Pharmacoepidemiological Rese-
arch in Primary Care1 of the Spanish Medication
Agency, which includes the participation of 10 autono-
mous communities and approximately 1,000 physicians,
integrates data on signs and symptoms, diagnosis, in-
dication and prescription, in addition to patient charac-
teristics. In the next few years, this database will allow
major advances to be made in the DUS performed in
primary care.
Importantly, the efficacy of this database will be de-
termined by its accessibility to the distinct research
groups. The Spanish Medication Agency should approve
the conditions for its use by researchers as soon as pos-
sible.
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